Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Acute Lymphoblastic Leukemia
92%
Pediatric Acute Lymphoblastic Leukemia
36%
Childhood Acute Lymphoblastic Leukemia
25%
Pediatric Patients
20%
L-asparaginase
20%
Methotrexate
19%
Leukemia Patients
18%
Dutch
18%
Netherlands
17%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
15%
Minimal Residual Disease
15%
KMT2A-rearranged
12%
Pharmacokinetics
12%
Oncology
11%
Event-free Survival
11%
Acute Myeloid Leukemia
10%
Pediatric
10%
Pegaspargase
10%
BCP-ALL
9%
Children with Cancer
9%
Population Pharmacokinetics (PopPK)
9%
Vincristine-induced Peripheral Neuropathy
9%
Pediatric Oncology
9%
Oral mucositis
8%
Childhood Cancer
8%
Maintenance Therapy
8%
Leukemia
8%
Pediatric Leukemia
8%
95% Confidence Interval
7%
Media Risks
7%
Ponte
7%
Improved Survival
7%
Steroid Resistance
7%
Newly Diagnosed
7%
Asparaginase Activity
7%
High Risk
7%
Young Adolescents
7%
International Consensus
7%
Peripheral Neuropathy
7%
Pediatric Cancer Patients
6%
Activity Level
6%
Randomized Controlled Trial
6%
Targeted Therapy
6%
Preadolescent children
6%
IKZF1 Deletion
6%
Overall Survival
6%
Blinatumomab
6%
Survivors
5%
Infant Acute Lymphoblastic Leukemia
5%
ETV6-RUNX1
5%
Quality of Survival
5%
MLL4
5%
Chemotherapy
5%
Pediatric T-cell Acute Lymphoblastic Leukemia
5%
High-dose Methotrexate (HD-MTX)
5%
Measuring Quality
5%
Sarcopenia
5%
Leucovorin
5%
Pediatric ALL
5%
Acute Lymphoblastic
5%
Consensus Statement
5%
Neuroblastoma
5%
Risk Factors
5%
6-mercaptopurine (6-MP)
5%
Leukemia Therapy
5%
Down Syndrome
5%
Survival Rate
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Pediatrics
50%
Childhood Cancer
29%
Malignant Neoplasm
27%
Minimal Residual Disease
21%
Adolescence
19%
Overall Survival
17%
Pediatrics Patient
16%
B Cell
14%
Acute Lymphocytic Leukemia
13%
Acute Myeloid Leukemia
13%
Diseases
12%
Maintenance Therapy
10%
Event Free Survival
10%
KMT2A
10%
Precursor
10%
Chemotherapy
10%
High Risk Population
10%
Vincristine
9%
Oncology
9%
Dexamethasone
9%
Survival Rate
8%
Ganglioneuroblastoma
8%
Clinical Trial
7%
Randomized Controlled Trial
7%
Pediatric Acute Myeloid Leukemia
7%
Pediatric Cancer
7%
Neuropathy
7%
Asparaginase
6%
Cohort Analysis
6%
Neoplasm
6%
Infection
5%
Leukemia
5%
Arm
5%
Infusion
5%
Bone Density
5%
Methotrexate
5%
Cancer-Related Fatigue
5%
Injection
5%
Childhood Acute Lymphocytic Leukemia
5%
Inotuzumab Ozogamicin
5%